openpr.com
Mobius Care Receives Funding from Crohn's & Colitis Foundation
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or ulcerative colitis.
Foundation funding signals institutional interest and support for precision diagnostics in IBD.
People with IBD (including those trying biologics or other advanced therapies), clinicians who treat IBD, and researchers working on biomarkers, digital pathology, or AI in gastroenterology.
What To Know
Mobius Care announced funding from the Crohn's & Colitis Foundation to advance an H&E image–based predictive biomarker that uses AI to predict response to existing IBD therapies.
The technology is described as a digital pathology test built on AI analysis of standard H&E slides and aims to support precision selection of treatments and development of therapeutics. This appears to be an early-stage diagnostic/biomarker development and funding announcement rather than publication of new clinical trial results.
The release references prior 2021 research by the team showing epithelial cell biomarkers could predict response, and frames the current funding as support to advance the AI-powered biomarker and an expanding therapeutic pipeline.
The piece is a press release about a funding partnership; it does not provide outcome data, performance metrics, or regulatory status for the biomarker.
This is a funding/press announcement about development of an AI-based H&E biomarker. It does not report new clinical validation results or regulatory approvals. Patients should not change treatments based on this release; follow-up publications or regulatory updates will be needed to judge clinical utility.
